youtube_live
Q3 2026 earnings • in 1 day
See detailschevron_right
GMAB:NASDAQ
Genmab A/S - ADR
$53.92
arrow_downward
-2.88%(-1.60) 1D
Nov 4, 11:11:39 AM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GMAB...
Open
$56.01
High
$56.20
Low
$53.76
Mkt. cap
33.74B
Avg. vol.
5.72M
Volume
1.73M
P/E ratio
42.49
52-wk high
$59.97
52-wk low
$23.62
EPS
$1.27
Beta
0.73
Shares outstanding
624.06M
No. of employees
3K
Open
$56.01
High
$56.20
Low
$53.76
Mkt. cap
33.74B
Avg. vol.
5.72M
Volume
1.73M
P/E ratio
42.49
52-wk high
$59.97
52-wk low
$23.62
EPS
$1.27
Beta
0.73
Shares outstanding
624.06M
No. of employees
3K
News stories
From web sources and news partners
Yahoo Finance
·
2 hours ago
Genmab to Present Results from Comprehensive Epcoritamab Development Program Highlighting Potential Across B-Cell Malignancies at the 2026 American Society of Hematology (ASH) Annual Meeting
GuruFocus
·
1 day ago
Genmab's Stock Surges on Cancer Drug Breakthroughs
Yahoo Finance
·
1 day ago
Genmab Stock Price Shock Puts 3 Oncology Biotech Names In Focus
Profile
Genmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schönharting, at the time managing director of BankInvest Biomedical venture fund. The company is based in Copenhagen, Denmark – internationally, it operates through the subsidiaries Genmab B.V. in Utrecht, The Netherlands, Genmab U.S., Inc. in Princeton, New Jersey, US, Genmab K.K. in Tokyo, Japan, Genmab Germany GmbH in München, Germany and Genmab Co., Ltd. in Suzhou, China. Genmab is listed on the Copenhagen Stock Exchange in Denmark, with American depositary receipts traded on the NASDAQ in the US. Wikipedia
About Genmab A/S - ADR
CEOJan G. J. van de Winkel
Employees3.12K
Founded1999
Headquarters-
SectorBiotechnology
Industry-
Websitegenmab.com